Business
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
CHICAGO, March 03, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8407d7267586f715337a2a7c5ddd8ab2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cjlwTk8A2KQyv9CZO4oTwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8407d7267586f715337a2a7c5ddd8ab2","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IVS6ou7S_GijhvJ_yUE1EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8407d7267586f715337a2a7c5ddd8ab2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, March 03, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.","length":435,"tagName":"p"},{"type":"text","content":""This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients," said Ryan Fukushima, CEO, Data & Apps at Tempus. "We’ve spent years configuring our Lens Platform to seamlessly leverage our library of de-identified multimodal data with the necessary AI computing power to train and fine-tune specific models for healthcare. Working with the great scientists at Merck, we have exciting opportunities to translate the insights from AI models into precision medicine strategies and improve patient outcomes across oncology and beyond."","length":678,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Merck will use Tempus’ de-identified data along with Tempus’ Lens Platform and Workspaces environment, which offers an advanced computational configuration powered by one of the industry’s largest GPU infrastructures, which enables researchers to efficiently conduct complex analyses on training-ready multimodal datasets, generating novel insights to accelerate the ...